Palbociclib

Palbociclib plus endocrine therapy was not associated with lowered quality of life among Black, indigenous and people of color with HR-positive, HER2-negative advanced breast cancer, according to research presented at ASCO 2021.

The oncotype DX assay better predicted the benefits of chemotherapy among patients with HR-positive breast cancer and one to three positive lymph nodes, according to findings from the RxPonder study presented at the San Antonio Breast Cancer Symposium.

In this video, Sara M. Tolaney, MD, MPH, discussed updated data from the phase I SERENA-1 trial,which was presented at the virtual San Antonio Breast Cancer Symposium.

The virtual format of this year’s San Antonio Breast Cancer Symposium had its negatives, like missing discussions with colleagues, and its positives, according to Elias Obeid, MD, MPH.

At the virtual San Antonio Breast Cancer Symposium, researchers presented results from the monarchE and PENELOPE-B trials that investigated ways to “improve cure rates and decrease recurrence rates among women with high-risk breast cancer.”

The addition of 1 year of palbociclib to endocrine therapy failed to improve invasive DFS among women with hormone receptor-positive, HER2-negative high-risk breast cancer, according to results of the phase 3 PENELOPE-B trial.

Combinations of cyclin-dependent kinase 4/6 inhibitors and aromatase inhibitors appeared effective among older and younger women with hormone receptor-positive, HER2-negative metastatic breast cancer compared with aromatase inhibitors alone, according to results of an FDA pooled analysis published in Journal of Clinical Oncology.

Adam Brufsky, MD, PhD, FACP, is a professor of medicine at the University of Pittsburgh School of Medicine. He also serves as associate division chief for the division of hematology/oncology in the University of Pittsburgh School of Medicine's Department of Medicine, medical director of the Magee-Women's Cancer Program, associate director for clinical investigations at UPMC Hillman Cancer Center and codirector of the Comprehensive Breast Cancer Center. Brufsky spoke with Healio about the TPS1103 trial, which will examine the addition of palbociclib to pertuzumab plus trastuzumab and an aromatase inhibitor in patients with HER2-positive, HR-positive breast cancer.

During the past decade, several key preclinical studies established the biologic rationale for targeting cyclin-dependent kinase 4/6 in women with hormone receptor-positive breast cancer.